Abstract：Objective: To study the curative efficacy of anerning granules combined with budesonide in treatment of bronchopneumonia and effects on serum insulin-like growth factor(IGF)- II, granulocyte-macrophage colony-stimulating factor(GM-CSF) and Solubility interleukin-2 receptor(sIL-2R) levels. Methods: 90 patients of bronchopneumonia who received therapy from March 2015 to March 2018 in our hospital were selected as research objects, according to the simple random number table, those patients were divided into the 44 cases of the observation group and the 46 cases of the control group, on the basis of routine treatment, the control group was treated with budesonide suspension, while the observation group was treated with anerning granules on the basis of the control group, they were treated continuously for 7 days. The clinical efficacy, the changes of the laboratory indexes, serum levels of IGF-II, GM-CSF, sIL-2R and adverse reactions were compared between the two groups. Results: The total effective rate of the observation group was 93.18%, which was significantly higher than that of the control group 73.91% (P<0.05); there were significant differences in C-reactive protein (CRP), white blood cell count (WBC), serum levels of IGF-II, GM-CSF and sIL-2R between the observation group and the control group after treatment [(1.79±0.30)mg/L vs (5.11±0.31)mg/L,(5.49±1.14)×109/L vs(7.26±1.52)×109/L,(0.39±0.04)ng/ml vs(0.67±0.08)ng/ml,(0.43±0.05)μg/L vs(0.71±0.09)μg/L, (132.83±11.51)pg/ml vs (159.47±14.74)pg/ml](P<0.05). The fever, cough, shortness of breath and lung rales disappeared times in the observation group were significantly shorter than that of the control group [(2.89±0.30)d vs (4.11±0.47)d, (4.05±0.49)d vs(5.29±0.55)d,(3.48±0.37)d vs(4.82±0.48)d,(3.27±0.40)d vs(4.71±0.45)d](P<0.05). There was no obvious adverse reaction in the two groups during treatment. Conclusion: In children with bronchial pneumonia, the use of Anerning Granule combined with budesonide suspension has a significant effect, which can help to reduce the expression of serum IGF-II, GM-CSF, sIL-2R, and promote the recovery of disease. It is safe and worthy of application and promotion.
[1] 钱前,季伟.2006年至2014年住院儿童呼吸道肺炎支原体感染的流行病学特征[J].重庆医学,2016,45(29):4113~4116. [2] Chand HS, Woldegiorgis Z, Schwalm K, et al. Acute inflammation induces insulin-like growth factor-1 to mediate Bcl-2 and Muc5ac expression in airway epithelial cells[J]. Am Respir Cell Mol Biol, 2012, 47(6): 784~791. [3] Li B, Han S, Liu F, et al. Budesonide Nebulization in the Treatment of Neonatal Ventilator Associated Pneumonia[J]. Pak Med Sci, 2017, 33(4): 997~1001. [4] 王海苹.安儿宁颗粒药理作用及临床应用[J].中国中医药现代远程教育,2014,12(3):160~161. [5] 胡亚美,江载芳,诸福棠.实用儿科学[M].第7版.北京:人民卫生出版社,2005.1174~1215. [6] Koch A, Kreutzer K, von Oldershausen G, et al. Inhaled glucocorticoids and pneumonia in preterm infants: post hoc results from the NEuroSIS trial[J]. Neonatology, 2017, 112(2): 110~113. [7] 师翠云.小儿支气管肺炎的临床诊治新进展[J].中国医药导报,2013,10(8):24~25. [8] 卢志锦,邝巧芬.安儿宁颗粒治疗小儿咳嗽的临床分析[J].中国实用医药,2013,8(32):136~137. [9] 闫淑玲.安儿宁颗粒治疗婴儿上呼吸道感染80例疗效观察[J].中国地方病防治杂志,2014,29(S2):206. [10] 陈永辉,陆宏进,张琪.安儿宁颗粒治疗小儿急性支气管炎(痰热咳嗽)的临床研究[J].中医儿科杂志,2014,10(4):15~18. [11] Nishimura M, Yamaguchi E, Takahashi A, et al. Clinical significance of serum anti-GM-CSF autoantibody levels in autoimmune pulmonary alveolar proteinosis[J]. Biomark Med, 2018, 12(2): 151~159
2019, Vol. 25 
冀公网安备13080202000677号